Nektar Therapeutics (NKTR)
-NasdaqGS | Prev Close: | 9.31 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | 11.00 x 1000 |
|---|
| 1y Target Est: | 12.38 |
|---|
| Beta: | 1.83 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 5.65 - 11.34 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 941,325 |
|---|
| Market Cap: | 1.07B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.62 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Data on AstraZeneca's NaloxegolZacks(Thu, May 23)
- NKTR Crosses Below Key Moving Average Levelat TheStreet(Wed, May 22)
- [$$] Digest Data on Nektar-AstraZeneca's Naloxegolat Barrons.com(Wed, May 22)
- Nektar Therapeutics' CEO Presents at UBS Global Healthcare Conference (Transcript)at Seeking Alpha(Tue, May 21)
- AstraZeneca says Phase III studies of Naloxegol met primary, secondary endpointsat theflyonthewall.com(Tue, May 21)
- ‘Love Hormone’ Promises Safer Births After Pfizer Flopat Bloomberg(Mon, May 20)
- July Options Now Available For Nektar Therapeuticsat Forbes(Mon, May 20)
- NEKTAR THERAPEUTICS FinancialsEDGAR Online Financials(Fri, May 17)
- Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York CityPR Newswire(Thu, May 16)
- Nektar Posts Wider Loss, Maintains ViewZacks(Wed, May 15)
- Nektar Therapeutics Increases Sales but Misses Estimates on Earningsat Motley Fool(Fri, May 10)
- Nektar Therapeutics Enters Oversold Territory (NKTR)at TheStreet(Fri, May 10)
- Nektar's CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Fri, May 10)
- Nektar Therapeutics Reports Financial Results for the First Quarter of 2013PR Newswire(Thu, May 9)
- NEKTAR THERAPEUTICS Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibEDGAR Online(Thu, May 9)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 12.46 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.08 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.44 |
|---|
| Mean Recommendation*: | 2.1 |
|---|
| PEG Ratio (5 yr expected): | -0.56 |
|---|
Business Summary
Nektar Therapeutics, a clinical-stage biopharmaceutical company, engages in developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms.
View More